trending Market Intelligence /marketintelligence/en/news-insights/trending/KB4axvDKEK6FEDaDEOzjoQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Ionis Pharmaceutical licenses experimental Alzheimer's therapy to Biogen

Blog

Banking Essentials Newsletter - February Edition

Blog

Message in a (Word)Cloud

Six trends shaping the industries and sectors we cover in 2021

Six trends shaping the industries and sectors we cover in 2021


Ionis Pharmaceutical licenses experimental Alzheimer's therapy to Biogen

Ionis Pharmaceuticals Inc. has licensed its experimental Alzheimer's disease therapy IONIS-MAPTrx to Biogen Inc.

Ionis earned $45 million from the licensing fee, with the possibility of receiving an additional $155 million in milestone payments, according to a Dec. 19 press release. Ionis, which develops RNA-targeted therapeutics, will also be eligible to receive future royalty payments in the low- to mid-teens based on sales of the medicine.

The agreement continues the companies' partnership in developing treatments for neurological disorders.

IONIS-MAPTrx is an antisense therapy that is designed to reduce the production of what is called microtubule-associated protein tau in the central nervous system. Microtubule-associated protein tau is thought to contribute or be the cause of multiple neurodegenerative diseases, including Alzheimer's disease and some forms of frontotemporal degeneration, according to Ionis.

Carlsbad, Calif.-based Ionis will be responsible for a current phase 1 clinical study of IONIS-MAPTrx in patients with mild Alzheimer's disease, which began in 2017. The company will also be responsible for a one-year long-term extension study that began in 2019.

Biogen will be responsible for any future studies of IONIS-MAPTrx and any further development, including regulatory filings and commercialization of the medicine, according to the press release.